A pilot program aimed at reducing Medicaid drug spending has limitations, according to a multi-institutional research team including faculty from Weill Cornell Medicine.
Launched November 2025, the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) program asks drug manufacturers to voluntarily reduce Medicaid’s prices to those paid by a group of seven peer nations including Canada, France, and the United Kingdom — a model known as Most Favored Nation pricing. States would then...